PR89766

BARCELONA, Spain, June 3, 2021 /PRNewswire=KYODO JBN/ --

-- The 28 systems to be deployed across KRC's three laboratory sites will test

about 94% of the country's blood donations

-- They will run the Procleix Ultrio Elite Assay, an advanced nucleic acid test

(NAT) ensuring donation safety by detecting the potential presence of the most

important infectious pathogens in a single, simultaneous test

-- Grifols has recently expanded its transfusion safety excellence in the

region, with more countries entrusting it to safeguard their blood supplies  

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the

development of plasma-derived therapies and innovative diagnostic solutions,

today announced it will provide the Korean Red Cross (KRC) with its

industry-leading Procleix Panther System running nucleic acid testing (NAT)

technology to help ensure the safety of South Korea's blood supply.

Logo - https://mma.prnewswire.com/media/463444/Grifols_Logo.jpg

As part of the KRC contract, Grifols will deliver 28 Procleix Panther Systems

that will be deployed during the following months across the humanitarian

organization's three laboratory sites in South Korea. When fully operational,

they will test about 94% of the country's blood donations, which are needed

mostly for transfusions.

The Procleix Panther Systems are known for their reliability, scalability and

versatility, providing high throughput with a small footprint while

streamlining laboratory workflow. They will feature the Procleix Ultrio Elite

Assay, a high-specificity NAT designed to improve blood safety by detecting the

potential existence of the most important infectious pathogens in a single,

simultaneous test from human serum or plasma.

"Increasingly countries in the Asia-Pacific region are relying on the

innovative, robust and efficient screening capabilities of the Procleix Panther

System to protect their blood supplies," said David Dew, President, Grifols

Diagnostic Commercial Division. "The combination of Grifols quality, safety and

cutting-edge technology is making an important difference in enhancing the

health and well-being of patients."

Grifols has steadily increased its transfusion safety leadership in

Asia-Pacific, where it currently screens more than half of all blood donations,

including 100% of those in Australia, Japan, Malaysia and New Zealand.

Grifols Korea, formed in 2020, is the company's most recent affiliate in

Asia-Pacific, where it has grown to 13 subsidiaries after first establishing

its presence in the region in 2000. China, where Grifols has a strategic

alliance with Shanghai RAAS, a leader in the country's plasma-derivatives

sector, is one of the company's most important markets in sales of Procleix NAT

solutions.

About the Procleix Panther System

The Procleix Panther System automates all aspects of NAT (Nucleic Acid

Testing)-based blood screening on a single, integrated platform, and is capable

of delivering the highest result throughput per square meter. It eliminates the

need for batch processing and combines walk-away freedom with intuitive design

for ease of use.

About Procleix NAT Solutions

Today, Procleix systems are used to screen more blood donations around the

world than any other NAT blood screening products, and include tests for HIV,

hepatitis viruses (A, B, C and E), West Nile virus, SARS-CoV-2*, Zika virus,

Dengue virus, Babesia, and more.

About Procleix Ultrio Elite Assay

The Procleix Ultrio Elite Assay is a nucleic acid test (NAT) that uses

magnetic-based target capture, Transcription-Mediated Amplification (TMA) and

chemiluminescence to detect HIV-1, HIV-2, HBV and HCV in serum or plasma of

donated blood. Because of the high sensitivity and specificity of the

technology, detection of the targeted pathogens can be achieved within the

early stages of infection, thereby helping to prevent infected blood or blood

components from being transfused even when the donor does not exhibit symptoms

and traditional serological screening techniques are not able to detect the

presence of the pathogen or antibodies against it. The assay runs on the

Procleix Panther System, a fully automated NAT instrument launched by Grifols

in the EU market in 2012 and currently widely used in laboratories globally.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed

to improving the health and well-being of people around the world. Its four

divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop,

produce and market innovative solutions and services that are sold in more than

100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation

centers worldwide. It transforms collected plasma into essential medicines to

treat chronic, rare and, at times, life-threatening conditions. As a recognized

leader in transfusion medicine, Grifols also offers a comprehensive portfolio

of solutions designed to enhance safety from donation to transfusion. In

addition, the company supplies tools, information and services that enable

hospitals, pharmacies and healthcare professionals to efficiently deliver

expert medical care.

Grifols, with nearly 24,000 employees in more than 30 countries and regions, is

committed to a sustainable business model that sets the standard for continuous

innovation, quality, safety and ethical leadership.

In 2020, Grifols' economic impact in its core countries of operation was EUR

7.5 billion. The company also generated 140,000 jobs, including indirect and

induced.

The company's class A shares are listed on the Spanish Stock Exchange, where

they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are

listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs

(NASDAQ:GRFS).

For more information, please visit www.grifols.com

*In development. Performance characteristics have not been established.

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical

data are "future projections and assumptions". Words and expressions such as

"believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will

seek to achieve", "it is estimated", "future" and similar expressions, in so

far as they relate to the Grifols group, are used to identify future

projections and assumptions. These expressions reflect the assumptions,

hypotheses, expectations and predictions of the management team at the time of

writing this report, and these are subject to a number of factors that mean

that the actual results may be materially different. The future results of the

Grifols group could be affected by events relating to its own activities, such

as a shortage of supplies of raw materials for the manufacture of its products,

the appearance of competitor products on the market, or changes to the

regulatory framework of the markets in which it operates, among others. At the

date of compiling this report, the Grifols group has adopted the necessary

measures to mitigate the potential impact of these events. Grifols, S.A. does

not accept any obligation to publicly report, revise or update future

projections or assumptions to adapt them to events or circumstances subsequent

to the date of writing this report, except where expressly required by the

applicable legislation. This document does not constitute an offer or

invitation to buy or subscribe shares in accordance with the provisions of the

following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October,

approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11

March and/or Royal Decree 1310/2005, of 4 November, and any regulations

developing this legislation. In addition, this document does not constitute an

offer of purchase, sale or exchange, or a request for an offer of purchase,

sale or exchange of securities, or a request for any vote or approval in any

other jurisdiction. The information included in this document has not been

verified nor reviewed by the external auditors of the Grifols group.

SOURCE: Grifols